N-(4-{[(3S)-3-(dimethylamino)pyrrolidin-1-yl]carbonyl}phenyl)-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-amine

DB07936ExperimentalSmall molecule

N-(4-{[(3S)-3-(dimethylamino)pyrrolidin-1-yl]carbonyl}phenyl)-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-amine: Overview.

Formula / weight: C₂₄H₃₀FN₇O · 451.5397 g/mol (avg)

Resolves to

Compound

ChEMBLCHEMBL460102PubChem16113377

Structure

InChIKeyBACSZMCLZIDTIO-IBGZPJMESA-NSMILES[H][C@@]1(CCN(C1)C(=O)C1=CC=C(NC2=NC(C3=CN=C(C)N3C(C)C)=C(F)C=N2)C=C1)N(C)C

Targets

P24941CDK2

What you can answer from here — as of April 02, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with N-(4-{[(3S)-3-(dimethylamino)pyrrolidin-1-yl]carbonyl}phenyl)-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-amine, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account